The Swiss company Noavartis is going to build a massive cancer therapy site in Denton.
Called a Radioligand therapy manufacturing site (RLT) - an advanced precision cancer treatment - it will be the company’s fifth in the US and first manufacturing facility in Texas, a part of the company's $23 billion investment in the US.
The Denton site is expected to create new jobs in bioengineering, advanced manufacturing, quality and operations, and will supporting economic growth in Denton and the surrounding communities.
“RLT has the potential to revolutionize cancer care,” said Vas Narasimhan, CEO of Novartis. “The addition of our fifth RLT manufacturing site in the US strengthens our ability to meet growing demand, building the capabilities needed to deliver these next-generation treatments with the speed and precision they require.”
Construction is scheduled to begin this year, with the site expected to become fully operational in 2028.
“Texas is a leading biotech hub and home to groundbreaking advancements in medicine,” said Governor Greg Abbott. “This significant investment by Novartis in Denton will establish their first manufacturing facility in Texas for cancer therapies and create good-paying jobs in bioengineering, advanced manufacturing, and more. Working together with innovative global leaders, we will continue to strengthen critical supply chains to help speed next-generation treatments to patients across Texas and the US.”
The Texas site will join a comprehensive Novartis RLT manufacturing network, with existing US sites in New Jersey, Indiana and California and a recently announced site to be constructed in Florida — providing unmatched RLT capacity from coast to coast. The manufacturing network has a longstanding record of enabling >99% of doses to be administered on the planned day. Each dose of RLT is custom-made and time-sensitive, making proximity to patients and treatment centers critical.
LISTEN on the Audacy App
Tell your Smart Speaker to "PLAY 1080 KRLD"
Sign Up to receive our KRLD Insider Newsletter for more news
Follow us on Facebook | Twitter | Instagram | YouTube